Immix Biopharma, Inc. (IMMX) fair value analysis
Nasdaq · Updated 2026-10-19
IMMX price how computed
Valuation status
No fair-value estimate yetIMMX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for IMMX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $7.98
- Sector
- Healthcare
- 12-month range
- $3.03–$14.47
- Market cap
- $662M
- From 52-week high
- -44.9%
- Shares outstanding
- 82.9M
- Rank in Healthcare by quality score
- #241 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Immix Biopharma, Inc. is a biopharmaceutical company that develops targeted therapies for patients with cancer and other serious diseases. The company is based in the United States and operates as a publicly traded entity on the Nasdaq exchange.
IMMX currently ranks #241 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $662M
- P/E (trailing)
- n/m
- EPS (TTM)
- $-0.88
- Debt / equity
- 0.00
- Shares outstanding
- 82.9M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 20 · oversold
- 50-day average
- $11.66
- 200-day average
- $9.32
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-06
- Last 8 quarters vs consensus
- 2 beat, 5 missed
- Quarter by quarter
- 2026-06 ▼ miss (-5.9%)
2026-03 ▲ beat (+14.3%)
2025-12 ▼ miss (-86.7%)
2025-09 ▼ miss (-26.3%)
2025-06 ▼ miss (-37.5%)
2025-03 ▲ beat (+34.8%)
2024-12 ▬ met (0.0%)
2024-09 ▼ miss (-50.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 0 hold · 0 sell (7 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $24.3
- Target vs last price
- +204.5%
What our data shows for IMMX
- Shares are trading in the middle of their 12-month price range of $3.03–$14.47.
- The 14-day relative strength index sits at an oversold 20.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- IMMX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the IMMX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is IMMX stock undervalued?
TickrTrends has no fair-value estimate for IMMX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is IMMX's TickrTrends verdict?
IMMX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does IMMX compare to other Healthcare stocks?
IMMX ranks #241 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is IMMX overbought or oversold?
IMMX's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does IMMX report earnings next?
IMMX's next earnings report is scheduled for 2026-11-06, per the published earnings calendar.
Does IMMX usually beat earnings estimates?
Over its last 8 reported quarters IMMX beat the consensus estimate 2 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about IMMX?
Of 7 analysts covering IMMX, 7 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $24.3 (+204.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.